Press Release Archive


  2017 / 2016 / 2015 / 2014 / 2013

Thursday, June 22, 2017

Cleveland researchers call for paradigm shift in type 2 diabetes treatment

CLEVELAND – Heart disease is a leading cause of death worldwide and exacerbated by type 2 diabetes, yet diabetes treatment regimens tend to focus primarily on blood sugar maintenance. This common approach to type 2 diabetes management can leave patients at risk for heart attack and stroke. But results from four recent randomized clinical trials suggest that using medications that offer glucose control while reducing the risk for cardiovascular disease could improve patient outcomes.
"Strong evidence provided by the four recent trials published within the past 1.5 to 2 years in the New England Journal of Medicine has shown that some of the modern available therapeutic agents that control blood glucose also help reduce the risk for cardiovascular disease," said Faramarz Ismail-Beigi, MD, PhD, Professor of Medicine at Case Western Reserve University and Endocrinologist at University Hospitals Cleveland Medical Center and Louis Stokes Cleveland VA Medical Center. "Based on this evidence, we propose that we must shift from our previous paradigm with its monocular focus on control of blood glucose and hemoglobin A1c, to one of control of blood glucose plus preventing cardiovascular disease and death from cardiovascular causes." Hemoglobin A1c is a common test used to determine a patient's average blood sugar levels over the previous 2-3 months.

Wednesday, June 07, 2017

Harrington Discovery Institute announces Gund-Harrington Scholars

CLEVELAND – Harrington Discovery Institute at University Hospitals in Cleveland, Ohio part of The Harrington Project for Discovery & Development, and the Foundation Fighting Blindness have announced their 2017 Gund-Harrington Scholars.
Harrington Discovery Institute partnerships are based on a shared mission to advance discoveries of new medicines that will improve human health, as well as, enhance each organization's ability to play a significant role in setting the scientific and innovation agenda in leading-edge research. These awards offer selected winners funding and drug development expertise to ensure the most promising treatments enter clinical trials where their safety and efficacy can be established.

Friday, June 02, 2017

Small molecule prevents blood clots without increasing bleeding risk

CLEVELAND – It may be possible to disrupt harmful blood clots in people at risk for heart attack or stroke without increasing their risk of bleeding, according to a new study published in Nature Communications.

The new research out of University Hospitals (UH) Cleveland Medical Center, Case Western Reserve University School of Medicine, and the Cleveland Clinic reveals a previously unknown cell receptor interaction that, when manipulated with therapeutic molecules, safely prevents blood clots. Approximately 100,000 Americans die annually from blood clots, or thrombosis, according to the Centers for Disease Control and Prevention.

“We have found a new thrombosis target that does not increase bleeding risk,” said senior author Daniel I. Simon, MD, President, UH Cleveland Medical Center, Herman K. Hellerstein Chair of Cardiovascular Research, and Professor of Medicine at Case Western Reserve School of Medicine. “Our discovery indicates that you can identify a new pathway and target that mediates blood clotting, but does not affect our body’s natural processes to stop bleeding, called hemostasis.”

Wednesday, May 24, 2017

Harrington Discovery Institute at University Hospitals opens call for Harrington Rare Disease Scholar Award

CLEVELAND – Harrington Discovery Institute at University Hospitals in Cleveland, Ohio – part of The Harrington Project for Discovery & Development – is pleased to announce its request for proposals for the Harrington Rare Disease Scholar Award. The Harrington Rare Disease Scholar Award supports breakthrough research for therapeutic discoveries in rare diseases. The program is sponsored by Takeda Pharmaceutical Company Limited (TSE: 4502) and overseen by Harrington Discovery Institute, a nonprofit initiative that helps academic researchers translate their most promising inventions into new medicines.

“We are excited to launch this new program with Takeda,” said Jonathan S. Stamler, MD, President, Harrington Discovery Institute and the Robert S. and Sylvia K. Reitman Family Foundation Distinguished Chair in Cardiovascular Innovation at University Hospitals and Case Western Reserve University School of Medicine. “The Harrington Rare Disease Scholar Award provides a unique opportunity to advance cutting-edge research in rare diseases into life-saving treatments.”

Thursday, May 18, 2017

University Hospitals celebrated opening of American Cancer Society Wig Salon

CLEVELAND –  University Hospitals Seidman Cancer Center celebrated the grand opening of their newest patient service, a free nail and wig salon called Le Salon on Thursday, May 18.  Wigs will be provided at the salon through the American Cancer Society Free Wig Salon program. The American Cancer Society provides this free community resource to help cancer patients manage the impact of cancer on their lives. The goal of the program is to provide a quality new wig free of charge in a safe comfortable environment.
“UH Seidman Cancer Center is a wonderful partner and we are pleased to be able to work together to help patients with some of the appearance related side effects of cancer treatment. Losing your hair due to treatment can be so devastating and we are happy to be able to ease this burden,” said Sarah Wells, executive director of the American Cancer Society.
The American Cancer Society can provide a human hair or synthetic hair wig, based on the woman’s preferences. In partnership with Pantene, the Society has provided more than 42,000 real-hair wigs to women coping with hair loss due to cancer.

You must be logged in to view this item.


This area is reserved for members of the news media. If you qualify, please update your user profile and check the box marked "Check here to register as an accredited member of the news media". Please include any notes in the "Supporting information for media credentials" box. We will notify you of your status via e-mail in one business day.